Altimmune Inc ALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.73
- Day Range
- $2.62–2.80
- 52-Week Range
- $2.56–7.73
- Bid/Ask
- $2.64 / $2.68
- Shares Outstanding
- 194.47M
- Market Cap
- $517.30M
- Volume/Avg
- 3M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7,604.46
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.altimmune.com
Valuation
|
Metric
|
ALT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.25 |
Price/Sales | 7,604.46 |
Price/Cash Flow | — |
Price/Earnings
ALT
Financial Strength
|
Metric
|
ALT
|
|---|---|
Quick Ratio | 29.43 |
Current Ratio | 29.56 |
Interest Coverage | −35.99 |
Quick Ratio
ALT
Profitability
|
Metric
|
ALT
|
|---|---|
Return on Assets (Normalized) | −31.87% |
Return on Equity (Normalized) | −37.73% |
Return on Invested Capital (Normalized) | −36.95% |
Return on Assets
ALT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Qqvrcsxr | Jhsqg | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tmxdvtqx | Gmyxf | $65B | |||
| argenx SE ADR
ARGX
| Xvbgcybtj | Xfw | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Twvgxrgm | Yltww | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Zgsjvylmn | Xynpr | $25B | |||
| BioNTech SE ADR
BNTX
| Zfmdsjqct | Gsgq | $22B | |||
| Incyte Corp
INCY
| Cqsnwtlm | Qtl | $21B | |||
| Moderna Inc
MRNA
| Fdxsfdkd | Qzgw | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Fqlkzhjyx | Mdhgf | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Qhwtqzqkf | Knv | $13B |
United States